Why Weight Management Often Requires Medical Support
Obesity is now recognised as a chronic, relapsing medical condition — not a character flaw or a failure of willpower. The neurobiological systems governing hunger, satiety, and energy expenditure are enormously complex. For many people with significant weight to lose, lifestyle changes alone are insufficient, and pharmaceutical support is both medically appropriate and clinically proven.
GLP-1 Receptor Agonists: The New Standard
Glucagon-like peptide-1 (GLP-1) receptor agonists represent the most significant advance in weight management pharmacology in decades. These medications mimic a naturally occurring gut hormone that signals fullness to the brain, slows gastric emptying, and reduces appetite at a neurological level.
Semaglutide (Wegovy, Ozempic) — Approved for chronic weight management at higher doses. Clinical trials showed an average weight loss of 15–17% of body weight over 68 weeks. The weekly subcutaneous injection format is well-tolerated by most patients.
Liraglutide (Saxenda) — A daily injection that produces average weight loss of 5–8% of body weight. A well-established option with a longer safety track record than newer agents.
Tirzepatide (Mounjaro) — A dual GIP/GLP-1 agonist showing even greater efficacy in trials, with average weight loss exceeding 20% of body weight in some studies.
Older Pharmaceutical Options
Orlistat (Xenical), phentermine, and combination medications such as naltrexone-bupropion (Contrave) remain available. They are typically less effective than GLP-1 agonists but may suit patients for whom the newer medications are contraindicated or unaffordable.
